Autorisation d’accès précoce refusée à la spécialité TEPEZZA (téprotumumab) dans l'indication « traitement des patients adultes atteints d’ophtalmopathie basedowienne modérée à sévère ».
See also
HAS opinions and decisions
26/02/2025
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
JDWWu82yjqAZHUJh
